FritsVan RheeMD

PubMed

• 2 citations
  Expression of integrin β-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics.
  Samrat Roy Choudhury, Stephanie D Byrum, Duah Alkam, Cody Ashby, Fenghuang Zhan, Alan J Tackett, Frits Van Rhee> ;Clinical Epigenetics. 2023 Feb 4
• 1 citations
  Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma.
  Samer Al Hadidi, Deepa Dongarwar, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D Shaughnessy, Frits van Rhee> ;Clinical Hematology International. 2023 Jun 1
• Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial.
  Samer Al Hadidi, Frits van Rhee> ;Journal of Clinical Oncology. 2023 Mar 20
• 7 citations
  Gamma-Tocotrienol Modulates Total-Body Irradiation-Induced Hematopoietic Injury in a Nonhuman Primate Model.
  Tarun K Garg, Sarita Garg, Isabelle R Miousse, Stephen Y Wise, Alana D Carpenter, Oluseyi O Fatanmi, Frits van Rhee, Vijay K Singh, Martin Hauer-Jensen> ;International Journal of Molecular Sciences. 2022 Dec 18
• Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients.
  Michael A Thompson, Mario Boccadoro, Xavier Leleu, Jorge Vela-Ojeda, Frits van Rhee, Katja C Weisel, Robert M Rifkin, Saad Z Usmani, Roman Hájek, Gordon Cook, Rafat Ab...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Mar 1
• 7 citations
  CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
  Sheila K Pierson, Laura Katz, Reece Williams, Melanie Mumau, Michael Gonzalez, Stacy Guzman, Ayelet Rubenstein, Ana B Oromendia, Philip Beineke, Alexander Fosså, Frits...> ;Nature Communications. 2022 Nov 24
• 5 citations
  Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.
  Meera Mohan, Lisa E Rein, Nishanth Thalambedu, Yetunde Ogunsesan, Munawwar Hussain, Jaskirat Sethi, Fatima Khan, Sravani Gundarlapalli, Lakshmi Yarlagadda, Binod Dhaka...> ;American Journal of Hematology. 2022 Dec 1
• 1 citations
  Ethnic Disparities in AL Amyloidosis Outcomes Among Hospitalized Patients in the United States.
  Samer Al Hadidi, Deepa Dongarwar, Hamisu Salihu, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee> ;Clinical Hematology International. 2022 Sep 1
• 6 citations
  Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
  Frits van Rhee, Adam Rosenthal, Karan Kanhai, Rabecka Martin, Katherine Nishimura, Antje Hoering, David C Fajgenbaum> ;Blood Advances. 2022 Aug 23
• 23 citations
  Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
  Carolina Schinke, Alexandra M Poos, Michael Bauer, Lukas John, Sarah Johnson, Shayu Deshpande, Luis Carrillo, Daisy Alapat, Leo Rasche, Sharmilan Thanendrarajan, Mauri...> ;Blood Advances. 2022 Nov 22
• 16 citations
  The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states.
  Leo Rasche, Carolina Schinke, Francesco Maura, Michael A Bauer, Cody Ashby, Shayu Deshpande, Alexandra M Poos, Maurizio Zangari, Sharmilan Thanendrarajan, Faith E Davi...> ;Nature Communications. 2022 Aug 3
• 1 citations
  Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis.
  Yoshito Nishimura, Midori Filiz Nishimura, David C Fajgenbaum, Frits van Rhee, Yasuharu Sato, Fumio Otsuka> ;Ejhaem. 2022 Aug 1
• 21 citations
  Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
  Raghad Alqazaqi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John Shaughnessy Jr, Fenghuang Zhan, Guido Tricot, Frits van Rhee, Samer Al Hadidi> ;JAMA Network Open. 2022 Aug 1
• 10 citations
  CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
  Dongzheng Gai, Jin-Ran Chen, James P Stewart, Intawat Nookaew, Hasem Habelhah, Cody Ashby, Fumou Sun, Yan Cheng, Can Li, Hongwei Xu, Bailu Peng, Tarun K Garg, Carolina...> ;The Journal of Clinical Investigation. 2022 Sep 15
• 1 citations
  The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
  David C Fajgenbaum, Sheila K Pierson, Karan Kanhai, Adam Bagg, Daisy Alapat, Megan S Lim, Mary Jo Lechowicz, Gordan Srkalovic, Thomas S Uldrick, Frits van Rhee> ;British Journal of Haematology. 2022 Jul 1
• 4 citations
  First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.
  Hassan Abushukair, Sebawe Syaj, Obada Ababneh, Aref Qarqash, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Samer Al Hadidi> ;American Journal of Hematology. 2022 Jul 1
• 3 citations
  Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
  Meera Mohan, Melody Renee Becnel, Urvi A Shah, Huaying Dong, Sravani Gundarlapalli, Timothy Peterson, Jennifer S Orozco, Sandra Horowitz, Saurabh Chhabra, Binod Dhakal...> ;American Journal of Hematology. 2022 Jul 1
• 6 citations
  Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma-Challenges and Potential Solutions.
  Samer Al Hadidi, Maurizio Zangari, Frits van Rhee> ;JAMA Oncology. 2022 Jun 1
• Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
  Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, Naveen Yarlagadda, Sunilkumar Kakadia, Manojna Konda, Anusha Jillella, Amisha Fnu, Yetunde Ogunsesan, Lakshmi Yarlagad...> ;American Journal of Hematology. 2022 Jun 1
• 3 citations
  Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
  Parvathi Sudha, Aarif Ahsan, Cody Ashby, Tasneem Kausar, Akhil Khera, Mohammad H Kazeroun, Chih-Chao Hsu, Lin Wang, Evelyn Fitzsimons, Outi Salminen, Patrick Blaney, M...> ;Clinical Cancer Research. 2022 Jul 1
• 1 citations
  Nearly 70 years later: the continued unraveling of Castleman disease.
  Frits Van Rhee> ;Haematologica. 2023 Jan 1
• 21 citations
  Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematol...
  Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee> ;JAMA Network Open. 2022 Apr 1
• 2 citations
  Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission.
  Kristin Larsen, Horace Spencer, Meera Mohan, Clyde Bailey, Kerri Hill, Mathew Kottarathara, Richa Parikh, Shadiqul Hoque, Amani Erra, Angel A Mitma, Pankaj Mathur, Lak...> ;Journal of Clinical Medicine. 2022 Mar 16
• 3 citations
  Optimisation of anti-interleukin-6 therapy: Precision medicine through mathematical modelling.
  Jean-François Rossi, Hao-Chun Chiang, Zhao-Yang Lu, Kalle Levon, Frits van Rhee, Karan Kanhai, David C Fajgenbaum, Bernard Klein> ;Frontiers in Immunology. 2022 Jan 1
• 7 citations
  Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
  Evan Lang, Brenda Sande, Samantha Brodkin, Frits van Rhee> ;Therapeutic Advances in Hematology. 2022 Jan 1
• Join now to see all

Abstracts/Posters

• Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Mutant KRAS Enhances Stress Granules and Resistance to Proteasome Inhibition Via 15-d-PGJ2 in Multiple Myeloma
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Quantitative Changes in Serum Proteins Including CXCL13 Are Early Indicators of Response to Anti-IL6 Therapy in Idiopathic Multicentric Castleman Disease
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• The Translational Switch of MYC Protein Aliases in Myeloma Tumor Cells
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Frits van Rhee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• The Mutational Landscape of Primary Plasma Cell Leukemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Extracting Prognostic Molecular Information from PET-CT Imaging of Multiple Myeloma Using Radiomic Approaches 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Long-Term Follow-up Identifies Double Hit and Key Mutations As Impacting Progression Free and Overall Survival in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all